MintNeuro

About MintNeuro

MintNeuro is a UK-based company developing a modular platform of semiconductor chips for next-generation neural implants. The company spun out of Imperial College London in 2022, founded by CEO Dr. Dorian Haci and CTO Professor Timothy Constandinou, leveraging over two decades of research in bioelectronics and neural interfaces. The founding team also includes Chief Scientific Officer Professor Andrew Jackson of Newcastle University and Chair of the Board Professor Tim Denison, a former VP at Medtronic. The company's formation was a culmination of extensive academic research, with Dr. Haci's transition from a PhD student and postdoctoral researcher to a Royal Academy of Engineering Enterprise Fellow being a key step in developing the business plan. MintNeuro addresses the core limitations of current neural implants, which are often bulky, power-hungry, and require invasive surgery. In contrast, MintNeuro's proprietary integrated circuits are designed to be ultra-low-power, highly integrated, and significantly smaller—some as small as a peppercorn—enabling minimally invasive procedures. MintNeuro operates on a horizontal business model, positioning itself as a foundational hardware provider for the entire neurotechnology industry rather than focusing on a single therapeutic device. It partners with medical device companies, research institutions, and clinical groups to integrate its function-specific chips into a variety of active implantable medical devices (AIMDs) and brain-computer interfaces (BCIs). The company's modular 'Lego block' approach allows for the combination of chips for functions like neural sensing, electrical stimulation, on-chip signal processing, and wireless communication to create application-specific systems. This adaptability allows partners to target a wide range of conditions, including epilepsy, Parkinson's disease, severe depression, and even urinary incontinence. Financially, MintNeuro has secured significant backing. In November 2024, it raised £1 million in a seed round led by Empirical Ventures, with participation from Parkwalk Advisors, Imperial College London, and Plug & Play. This adds to over £14 million in prior R&D grant funding from bodies such as Innovate UK and the Advanced Research and Invention Agency (ARIA). The company is engaged in several high-profile collaborations, including the DREAM project for epilepsy monitoring with King's College London and a partnership with Amber Therapeutics to develop a chipset for neuromodulation therapies. Keywords: neural implants, semiconductors, neurotechnology, medtech, integrated circuits, brain-computer interface, BCI, minimally invasive surgery, neuromodulation, bioelectronics, ASIC, chiplets, epilepsy treatment, Parkinson's disease, deep tech, Imperial College London spinout, Dorian Haci, Timothy Constandinou, low-power electronics, medical devices, neural sensing, electrical stimulation, neuro-aware systems, implantable medical devices, AIMD